---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-008482"
form_type: "8-K"
ticker: "CLNN"
cik: "0001822791"
company_name: "Clene Inc."
filed_at: "2026-03-17T23:59:59+00:00"
generated_at: "2026-05-15T10:47:06.317709+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Clene enters third-year NIH subaward with NYU for up to $8M for ALS expanded access program

## Summary
- Third-year subaward under $45.1M NIH grant; up to $8M for period 9/1/2025–8/31/2026.
- Funds support Expanded Access Program for CNM-Au8 treatment of amyotrophic lateral sclerosis (ALS).
- Subaward with New York University as prime awardee; replaces prior subaward with Columbia University for first two years.
- Either party may terminate with 30 days' notice; Company retains Background IP and no licenses granted to NYU or US Gov.

## SEC filing metadata
- accession: 0001437749-26-008482
- form_type: 8-K
- ticker: CLNN
- cik: 0001822791
- company_name: Clene Inc.
- filed_at: 2026-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822791/000143774926008482/0001437749-26-008482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822791/000143774926008482/clnn20260316_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-008482
- JSON: https://secwatch.observer/filing/0001437749-26-008482.json
- Plain text: https://secwatch.observer/filing/0001437749-26-008482.txt

## Key facts
- Material Agreements
  Clene Inc. entered into Year 3 Subaward with New York University (NYU) valued at up to $8.0 million (effective 2026-03-13).
  - Action: entry
  - Counterparty: New York University (NYU)
  - Value: up to $8.0 million
  - Effective: 2026-03-13
  source text: On March 13, 2026, the Company entered into a subaward agreement for the third year of the NIH Grant with New York University (“NYU”), the prime awardee, for up to $8.0 million during the period from September 1, 2025 to August 31, 2026 (the “Year 3 Subaward”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822791/000143774926008482/0001437749-26-008482-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.